Celltrion’s COVID-19 Treatment Regdanvimab Is Approved In Korea
Follows Conditional Approval In February From Korean Regulator
Celltrion continues to eye further markets for its CT-P59 regdanvimab monoclonal antibody treatment for COVID-19, especially in the EU, after winning final approval from the Korean Ministry of Food and Drug Safety.
You may also be interested in...
The European drugs regulator has given an overview of progress with the assessment of new vaccine candidates, additional and booster vaccines, and the use of vaccines in younger age groups.
The European Commission has set up a new expert group on virus variants whose tasks will include selecting the criteria for identifying possible new treatments and vaccines for COVID-19.
Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic.